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Introduction: Oxidative stress and endothelial damage are involved 
in the development and progression of diabetic nephropathy (DN). In 
this study, we investigated the effects of nitrosonifedipine (NO-NIF) 
having antioxidative property on DN with the endothelial dysfunction.
Patients (or Materials) and Methods: KKAy mice were used as a 
model of developing type II diabetes mellitus with the endothelial 
dysfunction. NO-NIF (30 mg/kg/d) was administrated continuously 
by intraperitoneally injection for 4 weeks. Histologic changes in the 
kidney, urinary protein, urinary albumin, oxidative stress, and blood 
glucose levels were evaluated. Moreover, we also examined whether 
NO-NIF affected the kidney dysfunction in eNOS knockout mice.
Results: In NO-NIF-–treated KKAy mice, the urinary protein and 
albumin were significantly decreased compared with nontreated 
KKAy mice. The pathologic analysis showed expanded glomeru-
lar mesangium in KKAy mice, which was suppressed by NO-NIF 
administration. However, NO-NIF had no effect on blood glucose 
in KKAy mice. NO-NIF decreased dihydroethidium staining in the 
kidney and 8-hydroxy-20-deoxyguanosine in the urine in KKAy mice. 
The expression of intercellular adhesion molecule-1, an endothelial 
cell damage marker, was decreased in the kidney by NO-NIF while 
the podocyte injury marker was not changed. The mRNA expression 
of TNF-α in kidney was also inhibited by NO-NIF. Furthermore, 
the administration of NO-NIF also suppressed the expansion of 
glomerular mesangial area and decreased urinary albumin in eNOS 
knockout mice.
Conclusion: NO-NIF prevents renal dysfunction associated with 
endothelial dysfunction independently of the blood glucose lowering, 
and it might be a potential drug for the prevention of DN.
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Introduction: Few studies have assessed the real-life impact of sec-
ondary prevention drugs on all-cause mortality postmyocardial 
infarction (MI), especially in countries with low incidence of MI. 
The objective of this interim analysis after 3.5-year of follow-up was 
to assess the real-life all-cause mortality impact of drugs reimbursed 
for MI secondary prevention in France: acetylsalicylic acid (ASA), 
antiplatelet agents (APA), beta-blockers (ß-), angiotensin-converting 
enzyme inhibitors (ACEI), statins, and omega-3 supplementation 
(Om3)
Patients (or Materials) and Methods: Cohort study of patients with 
recent (≤3 months) acute MI included by hospital and nonhospital 
cardiologists, with 6-year follow-up. Vital status was obtained from 
the National death registry, and failing that by patient/relatives/physi-
cians investigation. Drug exposure was defined using both physician 
and patient reports at inclusion. Cox proportional hazards model 
was used to estimate for each drug, mortality hazard ratio (HR) of 
exposed versus nonexposed patients, adjusted for gender, age, car-
diovascular risk factors, other MI prevention drugs, and propensity 
score to be exposed at inclusion. Results presented concern an interim 
analysis after 3.5 years of follow-up.
Results: Between May 2006 and June 2009, 596 physicians included 
5538 patients: mean age, 62.1 years, 77.6% male, 9.6% current 
smokers, 14.5% diabetic, 44.6% hypercholesterolemic, 43.6% 
hypertensive, and 8.2% with LVEF < 40%. At inclusion, 97.5% 
were exposed to ASA, 91.0% to APA, 89.7% to ß-, 71.1% to ACEI, 
92.0% to statins, and 15.7% to Om3. The 3.5-year mortality was 
7.8% (95%CI, [7.1%> 8.5%]) with an incidence rate of 23.2 per 
1000 patient-years. Adjusted HR were: 0.98 [0.60–1.61] for ASA, 
0.86 [0.60–1.24] for APA, 0.84 [0.63–1.11] for ß-, 0.80 [0.61–1.03] 
for ACEI, 0.67 [0.45–1.00] for statins, and 0.82 [0.58–1.16] for 
Om3.
Conclusion: The 3.5-year interim all-cause real-life death reduction 
point estimates were close to those of large randomized controlled 
trials, except for ASA, for which almost all patients were exposed. 
The study’s statistical power will be sufficient to confirm or not these 
trends at the final 6-year analysis.
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Introduction: Effective flow through conduit arteries is important 
both for in situ organ perfusion and for tissue function after surgi-
cal and other procedures for revascularization. Membrane-bound, 
calcium-independent phospholipase A2 (iPLA2β ) has been impli-
cated in G-protein coupled receptor-mediated vasoconstriction in 
experimental studies using Sbromoenolactone (S-BEL) as a probe. 
However, the role of iPLA2β is unclear with regard to the regulation 
of vascular tone in humans. S-BEL selectively inhibits iPLA2β . It also 
inhibits other serine hydrolases, including phosphatidate phospho-
hydrolase-1 (PAP-1).
Patients (or Materials) and Methods: We studied human internal 
mammary (IMA) arteries obtained during coronary artery surgery 
and assessed iPLAβ in silico and responses in vitro to S-BEL, its 
enantiomer R-BEL, and propranolol of vessels preconstricted with 
phenylephrine (PE) to 80% of maximum response. All patients were 
undergoing surgery for treatment of ischemic heart disease and gave 
written informed consent to the study, which was approved by the 
local research ethics committee. Data are shown as means and stand-
ard errors. Data were compared by paired (Wilcoxon) or multi-way 
(Friedman) nonparametric tests.
Results: Compared with PE alone, contraction to PE increased dur-
ing incubation of IMA segments in the presence of SBEL 25μ M (PE 
alone, 6.9 [2.4 ] [SE] mN; PE with S-BEL, 12.7 [2.5] mN; P = 0.028, 
Wilcoxon] in contrast to time-dependent decreased contraction to 
